Trumpeter of  Alzheimer's conundrum. As CEO and Chairman of Pitney Bowes, Mr. Critelli was another who lent his voice to the call for quality-enhanced outcomes. (McGlynn is a fan, which is just about all we needed to know.) At Pitney, his focus was always to invest more in prevention, diagnosis and disease management, than on technologies for addressing acute diseases, he says, "because we can have a more positive impact on more people and can lower costs at the same time." (We think so, too) Since leaving Pitney he has continued to advocate for cost-reductions and has, in particular, patronized work being done in Alzheimer's because it is already the third-costliest disease, and yet lags in funding compared with HIV/AIDS, cancer, and heart diseases. This is an area of health costs that is ballooning. It needs Critelli.

quoting The Wall Street Journal on his blog:

"…a dollar spent on medical care is a dollar of income for someone. ..It may be the single most important fact about health care in America that you or I need to know."